$38.41
-0.20 (-0.52%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
+48.19%
YTD
+13.47%
Open$38.88
Previous Close$38.61
Day High$39.25
Day Low$38.15
52W High$42.68
52W Low$24.28
Volume—
Avg Volume586.4K
Market Cap3.63B
P/E Ratio—
EPS$-1.94
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$34.24
Above
SMA 200
$27.52
Above
RSI (14)
49.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
22 analysts
Price Target
+206.4% upside
Current
$38.41
$38.41
Target
$117.67
$117.67
$81.99
$117.67 avg
$158.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 238.94M | 147.00M | 384.15M |
| Net Income | -124,210,213 | -68,776,419 | -80,984,777 |
| Profit Margin | -52.0% | -49.4% | -21.1% |
| EBITDA | -171,094,759 | -100,000,012 | -85,173,040 |
| Free Cash Flow | — | — | -100,075,430 |
| Rev Growth | +62.5% | +62.5% | -7.8% |
| Debt/Equity | — | — | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.96 | -0.02% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $385.65 | +1.55% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.11 | -0.52% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $508.34 | -1.55% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $784.85 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $239.56 | -2.42% | 40.0 | 32.33B |